Bioniq, a personalized supplement provider based in London, UK, has raised $15M in Series B funding.

The investment round was led by HV Capital and Unbound. The funds will be used to expand Bioniq's global market share.

Bioniq, valued at $75M, leverages AI-driven analysis of blood biomarker data to develop customized supplement formulas. The company has served over 100,000 users worldwide.

CEO Vadim Fedotov emphasized the importance of personalized health, saying, "Our AI-driven approach creates customized supplements that provide quantifiable results and cater to individuals’ specific needs." Bioniq aims to set new standards in the industry by ensuring process and result transparency for users.